Zinc Acetate Hydrate Supplementation versus Polaprezinc Supplementation for Improving Hypozincemia in Hemodialysis Patients: A Randomized Clinical Trial
Zinc supplementation may ameliorate zinc deficiency in maintenance hemodialysis patients; however, no standard protocol has been established. This study aimed to investigate the effects of zinc acetate hydrate (ZAH) and polaprezinc (PPZ) as zinc supplements in hemodialysis patients. We enrolled 75 h...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2023/2403755 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547843532914688 |
|---|---|
| author | Etsuko Kumagai Kazuhiro Furumachi Akihiro Kurihara Ken Hosokawa Keiko Hosohata Shinji Takai |
| author_facet | Etsuko Kumagai Kazuhiro Furumachi Akihiro Kurihara Ken Hosokawa Keiko Hosohata Shinji Takai |
| author_sort | Etsuko Kumagai |
| collection | DOAJ |
| description | Zinc supplementation may ameliorate zinc deficiency in maintenance hemodialysis patients; however, no standard protocol has been established. This study aimed to investigate the effects of zinc acetate hydrate (ZAH) and polaprezinc (PPZ) as zinc supplements in hemodialysis patients. We enrolled 75 hemodialysis patients with serum zinc levels <60 μg/dL for this study and randomly assigned Zinc supplementation to these 75 patients: 37 received ZAH (50 mg/day), and 38 received PPZ (34 mg/day). Serum zinc levels of both groups were compared every 4 weeks for 1 year. In both groups, serum zinc levels significantly increased at 4–52 weeks. Serum zinc levels were significantly higher in the ZAH group at 4–12 weeks; however, no significant differences were observed between the groups at 16–52 weeks. Adverse events requiring a reduction in the zinc dose, including copper deficiency, occurred significantly more frequently in the ZAH group. In conclusion, PPZ can safely maintain serum zinc levels for 1 year. ZAH provides rapid zinc supplementation but can cause adverse events. |
| format | Article |
| id | doaj-art-5eed0a637faf4bd4a76d61fb9abdc291 |
| institution | Kabale University |
| issn | 2090-2158 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-5eed0a637faf4bd4a76d61fb9abdc2912025-02-03T06:43:09ZengWileyInternational Journal of Nephrology2090-21582023-01-01202310.1155/2023/2403755Zinc Acetate Hydrate Supplementation versus Polaprezinc Supplementation for Improving Hypozincemia in Hemodialysis Patients: A Randomized Clinical TrialEtsuko Kumagai0Kazuhiro Furumachi1Akihiro Kurihara2Ken Hosokawa3Keiko Hosohata4Shinji Takai5Kenwakai HospitalKenwakai HospitalJapanese Red Cross Society Shimoina Red Cross HospitalShimoina Kosei HospitalEducation and Research Center for Clinical PharmacyDepartment of Innovative MedicineZinc supplementation may ameliorate zinc deficiency in maintenance hemodialysis patients; however, no standard protocol has been established. This study aimed to investigate the effects of zinc acetate hydrate (ZAH) and polaprezinc (PPZ) as zinc supplements in hemodialysis patients. We enrolled 75 hemodialysis patients with serum zinc levels <60 μg/dL for this study and randomly assigned Zinc supplementation to these 75 patients: 37 received ZAH (50 mg/day), and 38 received PPZ (34 mg/day). Serum zinc levels of both groups were compared every 4 weeks for 1 year. In both groups, serum zinc levels significantly increased at 4–52 weeks. Serum zinc levels were significantly higher in the ZAH group at 4–12 weeks; however, no significant differences were observed between the groups at 16–52 weeks. Adverse events requiring a reduction in the zinc dose, including copper deficiency, occurred significantly more frequently in the ZAH group. In conclusion, PPZ can safely maintain serum zinc levels for 1 year. ZAH provides rapid zinc supplementation but can cause adverse events.http://dx.doi.org/10.1155/2023/2403755 |
| spellingShingle | Etsuko Kumagai Kazuhiro Furumachi Akihiro Kurihara Ken Hosokawa Keiko Hosohata Shinji Takai Zinc Acetate Hydrate Supplementation versus Polaprezinc Supplementation for Improving Hypozincemia in Hemodialysis Patients: A Randomized Clinical Trial International Journal of Nephrology |
| title | Zinc Acetate Hydrate Supplementation versus Polaprezinc Supplementation for Improving Hypozincemia in Hemodialysis Patients: A Randomized Clinical Trial |
| title_full | Zinc Acetate Hydrate Supplementation versus Polaprezinc Supplementation for Improving Hypozincemia in Hemodialysis Patients: A Randomized Clinical Trial |
| title_fullStr | Zinc Acetate Hydrate Supplementation versus Polaprezinc Supplementation for Improving Hypozincemia in Hemodialysis Patients: A Randomized Clinical Trial |
| title_full_unstemmed | Zinc Acetate Hydrate Supplementation versus Polaprezinc Supplementation for Improving Hypozincemia in Hemodialysis Patients: A Randomized Clinical Trial |
| title_short | Zinc Acetate Hydrate Supplementation versus Polaprezinc Supplementation for Improving Hypozincemia in Hemodialysis Patients: A Randomized Clinical Trial |
| title_sort | zinc acetate hydrate supplementation versus polaprezinc supplementation for improving hypozincemia in hemodialysis patients a randomized clinical trial |
| url | http://dx.doi.org/10.1155/2023/2403755 |
| work_keys_str_mv | AT etsukokumagai zincacetatehydratesupplementationversuspolaprezincsupplementationforimprovinghypozincemiainhemodialysispatientsarandomizedclinicaltrial AT kazuhirofurumachi zincacetatehydratesupplementationversuspolaprezincsupplementationforimprovinghypozincemiainhemodialysispatientsarandomizedclinicaltrial AT akihirokurihara zincacetatehydratesupplementationversuspolaprezincsupplementationforimprovinghypozincemiainhemodialysispatientsarandomizedclinicaltrial AT kenhosokawa zincacetatehydratesupplementationversuspolaprezincsupplementationforimprovinghypozincemiainhemodialysispatientsarandomizedclinicaltrial AT keikohosohata zincacetatehydratesupplementationversuspolaprezincsupplementationforimprovinghypozincemiainhemodialysispatientsarandomizedclinicaltrial AT shinjitakai zincacetatehydratesupplementationversuspolaprezincsupplementationforimprovinghypozincemiainhemodialysispatientsarandomizedclinicaltrial |